Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes SEATTLE, June 09, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced an upcoming podium presentation highlighting ongoing clinical data from the investigator-sponsored, first-in-human study transpla...
Solésence Expands Debt Facilities to Fuel Growth Initiatives ROMEOVILLE, Ill., June 02, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it entered into amendments on May 27, 2025 to its existing loan agreements, providing increased borrowing capacity to support the execution of strategic objectives. The new facility expands the Company’s three loan agreements to a maximum borrowing capacity from $14.2 million to $23.0 million and extends the maturity date und...
We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...
Sana Biotechnology to Present at June 2025 Investor Conferences SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update. Sana will present at the Jefferies Global Healthcare Conference at 2:35 p.m. ET on Wednesday, June 4, 2025.Sana will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 8:40 a.m. ET on Tues...
Mercury Introduces First Safety-Certifiable, SOSA-aligned Mission Computer for Aviation Platforms Company demonstrating multiple mission computing technologies at the Army Aviation Mission Solutions Summit 2025, May 14-16 in Nashville, Tenn. ANDOVER, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, ), a technology company that delivers mission-critical processing power to the edge, today introduced the first safety-certifiable, SOSA-aligned aviation mission computer, which will allow government and commercial organizations to field and modernize aircraft that...
Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference SEATTLE, May 12, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the BofA Securities 2025 Healthcare Conference at 9:20 a.m. PT on Tuesday, May 13, 2025. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Sana’s website a...
Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates Presented positive 4- and 12-week clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with stable C-peptide production post-transplant Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect to report clinical data from both studies in 2025...
Mercury Systems Reports Third Quarter Fiscal 2025 Results Q3 FY25 Bookings of $200.4 million; trailing-twelve-month book-to-bill of 1.1Backlog of $1.34 billion; up 4% year-over-yearQ3 FY25 Revenue of $211.4 million; GAAP net loss of $19.2 million; and adjusted EBITDA of $24.7 millionOperating Cash Flow of $30.0 million with Free Cash Flow of $24.1 million ANDOVER, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, ), reported operating results for the third quarter of fiscal year 2025, ended March 28, 2025. “We delivered solid results in the third quarter of fi...
Solésence Reports Record First Quarter 2025 Financial Results First quarter revenue increased 48% to a record $14.6 million ROMEOVILLE, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the first quarter ended March 31, 2025. Recent Highlights and Accomplishments Uplisted to Nasdaq under the ticker “SLSN” supporting the Company’s increased visibility with the investment communityAchieved record revenue and unit volume shipments...
Mercury Acquires Star Lab to Advance Its Leadership Position in Secure Processing ANDOVER, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, ), a technology company that delivers mission-critical processing to the edge, today announced the closure of an agreement that will further advance the company’s leadership position in secure processing capabilities for aerospace and defense applications. Mercury has completed the acquisition of Star Lab, a subsidiary of Wind River Systems, Inc., that provides anti-tamper and cybersecurity software solutions designed to p...
Solésence To Report First Quarter 2025 Financial Results and Host a Conference Call ROMEOVILLE, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Romeoville, Ill., April 28, 2025 – Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the first quarter of 2025 after the market close on Monday, May 5, 2025, and host a conference call and webcast on the same date. First Quarter 2025 Conference Call Details Date / Time: Monday, May 5, 2025 - 4:00 p.m. CDT, 5:00 p.m. ...
Mercury Systems to Report Third Quarter Fiscal Year 2025 Financial Results on May 6, 2025 ANDOVER, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Mercury Systems Inc. (NASDAQ: MRCY, ), a technology company that delivers mission-critical processing power to the edge, will release its third quarter fiscal year 2025 financial results after the market close on Tuesday, May 6, 2025. Management will host a conference call and simultaneous webcast at 5:00 p.m. ET on the same day to discuss Mercury's quarterly financial results, business highlights, and outlook. In addition, Company representatives m...
Mercury and Cicor Group Create Long-Term Strategic Business Relationship In Support of European Defense ANDOVER, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, ), a technology company that delivers mission-critical processing power to the edge, today announced it has entered into a strategic supply agreement under which Cicor Group (SIX Swiss Exchange: CICN) will acquire a manufacturing operation in Plan-Les-Ouates, Switzerland, and supply Mercury with electronic products over the next five years. Mercury Mission Systems International S.A. is a leading p...
Solésence Announces Uplisting to Nasdaq Trading set to begin Tuesday, April 8 under new ticker “SLSN” ROMEOVILLE, Ill., April 07, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (OTCQB: NANX), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it has received approval from the Listing Qualifications Department of Nasdaq to transfer its listing to the Nasdaq Capital Market. The Company’s securities will be uplisted to Nasdaq at the opening of business on Tuesday, April 8, 2025. Prior to listing on Nasdaq, the Company’s shares t...
Solésence Reports Record Fourth Quarter and Full-Year 2024 Financial Results Fourth quarter revenue increased 58% to a record $12.6 million Full Year 2024 revenue increased 40% to a record $52.3 million ROMEOVILLE, Ill., March 26, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (OTCQB: NANX), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the fourth quarter and year ended December 31, 2024. Recent Highlights and Accomplishments Company rebranded as Solésence, Inc., marking a new era of innovation, se...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.